Skip to content

Clinical trials

Observational Leukemia, Myelomonocytic, Chronic trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Leukemia, Myelomonocytic, Chronic Phase: Observational Clear all

41 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20042
20051
20063
20072
20087
20096
20104
20111
20122
20141
20151
20171
20181
20221
20242
20252
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed19
Terminated9
Recruiting7
Withdrawn3
Active, not recruiting1
Not yet recruiting1
Unknown status1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
City of Hope Medical Center3
Vanderbilt-Ingram Cancer Center3
Bristol-Myers Squibb2
Case Comprehensive Cancer Center2
Celgene2
Children's Oncology Group2
SWOG Cancer Research Network2
Vanderbilt University2
Arbeitsgemeinschaft medikamentoese Tumortherapie1
Blueprint Medicines Corporation1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Leukemia, Myelomonocytic, Chronic41
Leukemia, Myeloid, Acute30
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative25
Leukemia, Lymphocytic, Chronic, B-Cell24
Myelodysplastic Syndromes24
Precursor Cell Lymphoblastic Leukemia-Lymphoma24
Congenital Abnormalities23
Leukemia22
Leukemia, Hairy Cell22
Blast Crisis21

Trials

Showing 26 to 41 of 41. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.